MoonLake Immunotherapeutics (MLTX)
51.86
+2.04
(+4.09%)
USD |
NASDAQ |
Nov 21, 16:00
52.02
+0.16
(+0.30%)
After-Hours: 20:00
MoonLake Immunotherapeutics Total Liabilities (Quarterly): 22.71M for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 22.71M |
| June 30, 2024 | 14.85M |
| March 31, 2024 | 11.73M |
| December 31, 2023 | 13.05M |
| September 30, 2023 | 10.58M |
| June 30, 2023 | 7.511M |
| Date | Value |
|---|---|
| March 31, 2023 | 7.685M |
| December 31, 2022 | 8.077M |
| September 30, 2022 | 6.024M |
| June 30, 2022 | 3.876M |
| December 31, 2021 | 21.33M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
3.876M
Minimum
Jun 2022
22.71M
Maximum
Sep 2024
11.58M
Average
10.58M
Median
Sep 2023
Total Liabilities (Quarterly) Benchmarks
| Novartis AG | 60.08B |
| AC Immune SA | 135.61M |
| CRISPR Therapeutics AG | 316.47M |
| Addex Therapeutics Ltd | 1.164M |
| NLS Pharmaceutics Ltd | 10.46M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 518.21M |
| Shareholders Equity (Quarterly) | 488.20M |